Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBT: 2009-2025

Historic EBT for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $7.6 million.

  • Gyre Therapeutics' EBT rose 94.12% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 119.62%. This contributed to the annual value of $23.2 million for FY2024, which is 130.17% up from last year.
  • Latest data reveals that Gyre Therapeutics reported EBT of $7.6 million as of Q3 2025, which was up 240.88% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' EBT ranged from a high of $51.6 million in Q2 2022 and a low of -$100.3 million during Q4 2023.
  • Moreover, its 3-year median value for EBT was $5.9 million (2023), whereas its average is -$3.6 million.
  • In the last 5 years, Gyre Therapeutics' EBT plummeted by 453.20% in 2021 and then surged by 359.09% in 2022.
  • Over the past 5 years, Gyre Therapeutics' EBT (Quarterly) stood at -$20.3 million in 2021, then fell by 12.27% to -$22.8 million in 2022, then slumped by 339.82% to -$100.3 million in 2023, then spiked by 100.77% to $772,000 in 2024, then spiked by 94.12% to $7.6 million in 2025.
  • Its EBT stands at $7.6 million for Q3 2025, versus $2.2 million for Q2 2025 and $4.6 million for Q1 2025.